comparemela.com

Latest Breaking News On - தலைமை ப்ரொடக்ஶந் அதிகாரி - Page 5 : comparemela.com

Celonic to produce 100 million doses of CureVac s COVID-19 vaccine

Novartis joins effort to produce CureVac vaccine for Covid-19

Article by Adam Duckett CureVac AG NOVARTIS has signed an agreement to manufacture CureVac’s Covid-19 vaccine candidate at its site in Kundl, Austria. Novartis plans to manufacture the mRNA and bulk drug product of CureVac’s CVnCoV, with 50m doses expected by the end of 2021, and 200m in 2022. CureVac has said that preparations for the start of production, technology transfers and test runs are already underway, with delivery of the first doses expected to start in Q3. CVnCoV entered phase three clinical trials in December, and CureVac has begun a rolling submission of data to the European medicines regulators to help streamline approval for the drug’s use.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.